Last updated: August 3, 2026
Indivior Inc. sued Actavis Laboratories UT, Inc. in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act after Actavis filed an abbreviated new drug application for generic buprenorphine and naloxone sublingual film. The case concerned Indivior’s Suboxone Film product and patents covering the film’s composition, dosage form, polymer matrix, and delivery characteristics.
The litigation was part of a broader patent campaign against generic manufacturers seeking approval to market buprenorphine/naloxone sublingual film. Its commercial importance was high because Suboxone Film was Indivior’s principal opioid-dependence product and the asserted patents were intended to delay generic competition beyond the expiration of the original Suboxone tablet patents.
What was Indivior Inc. v. Actavis Laboratories UT, Inc. about?
The action was a Hatch-Waxman patent infringement case arising from Actavis’s ANDA filing for a generic version of Suboxone Film. Indivior alleged that Actavis’s proposed product would infringe patents listed in the FDA’s Orange Book.
The case number was 1:18-cv-00497. The action was assigned to Judge Richard G. Andrews in the District of Delaware.
| Item |
Details |
| Plaintiff |
Indivior Inc. |
| Defendant |
Actavis Laboratories UT, Inc. |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:18-cv-00497 |
| Technology |
Buprenorphine/naloxone sublingual film |
| Product |
Suboxone Film |
| Regulatory framework |
Hatch-Waxman Act, 21 U.S.C. § 355(j) |
| Filing year |
2018 |
| Primary dispute |
Whether Actavis’s ANDA product infringed Indivior’s Orange Book-listed patents |
Actavis Laboratories UT was associated with Teva Pharmaceuticals’ generic-drug operations. The litigation was one of several cases filed by Indivior against companies seeking to market generic buprenorphine/naloxone film.
What patents protected Suboxone Film in the Actavis litigation?
The principal patent family involved Indivior’s polymeric film technology. The patents addressed how buprenorphine and naloxone are incorporated into a rapidly dissolving oral film and how the film delivers the active ingredients through the oral mucosa.
The litigation record and related Suboxone Film cases identify the following patents as central to Indivior’s enforcement program:
| Patent |
General subject matter |
Relevance to Suboxone Film |
| U.S. Patent No. 8,603,514 |
Drug-containing film and dosage form |
Covered aspects of the film composition and delivery system |
| U.S. Patent No. 8,900,497 |
Film composition and manufacturing-related characteristics |
Addressed the polymeric film matrix and dosage form |
| U.S. Patent No. 9,687,454 |
Sublingual or buccal film dosage form |
Covered formulation and delivery features |
| U.S. Patent No. 9,931,305 |
Buprenorphine/naloxone film formulation |
Covered later-generation Suboxone Film claims |
The precise patent claims at issue depended on the pleadings, Actavis’s ANDA specifications, claim construction, and the parties’ narrowing of the case. The core technical issue was whether Actavis’s proposed film had the claimed combination of active pharmaceutical ingredients, water-soluble polymers, buffers, film thickness or dosage characteristics, and oral-dissolution properties.
What was the litigation timeline?
The case followed the standard ANDA litigation sequence.
| Date or period |
Event |
| 2018 |
Indivior filed the patent infringement action after receiving notice of Actavis’s ANDA Paragraph IV certification |
| 2018-2019 |
The parties litigated claim construction and pretrial issues |
| 2019-2020 |
The court considered motions concerning infringement, validity, and the scope of the asserted claims |
| 2020 onward |
The case proceeded against the backdrop of Federal Circuit decisions addressing related Indivior Suboxone Film patents |
| Later proceedings |
The commercial effect of the case was shaped by generic approvals, related patent decisions, and the expiration or invalidation of portions of Indivior’s patent estate |
The statutory 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii) was an important regulatory consequence of the complaint. The stay generally prevents FDA approval of the ANDA for up to 30 months unless the court enters an earlier judgment or the litigation is otherwise resolved.
Did Actavis file a Paragraph IV challenge?
Yes. The action was based on Actavis’s ANDA-related Paragraph IV position.
A Paragraph IV certification states that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The certification creates an artificial act of infringement under 35 U.S.C. § 271(e)(2), allowing the patent owner to sue before commercial marketing begins.
For Indivior, the Paragraph IV challenge created litigation exposure across several patent categories:
- formulation claims directed to the buprenorphine/naloxone film;
- dosage-form claims directed to sublingual administration;
- polymer and film-matrix claims;
- manufacturing and product-property claims;
- later-filed continuation or divisional claims intended to extend protection around the commercial product.
Actavis’s Paragraph IV challenge did not automatically establish a right to launch. Actavis still had to overcome infringement and validity arguments, while Indivior had to prove that the ANDA product met every limitation of at least one asserted claim.
How strong was Indivior’s patent estate?
Indivior’s patent estate had meaningful technical coverage but faced substantial validity pressure.
The strongest commercial position came from patents directed specifically to the marketed film product rather than broad claims covering buprenorphine therapy generally. Those claims could be valuable if they captured the structural and functional characteristics that generic manufacturers had to reproduce to obtain approval.
The principal weaknesses were:
-
Written-description exposure. Several Suboxone Film patents claimed broad ranges or product characteristics that were challenged as broader than the original disclosure.
-
Obviousness risk. Buprenorphine, naloxone, oral films, water-soluble polymers, and transmucosal delivery were individually known technologies. The patentability question depended on the claimed combination and the evidence regarding formulation development.
-
Claim-construction sensitivity. Small differences in the interpretation of polymer, dosage, water-content, or dissolution limitations could determine the outcome.
-
Continuation-estate vulnerability. Later patents could provide additional litigation positions, but continuation claims remained exposed to written-description, obviousness-type double-patenting, and prosecution-history challenges.
The most significant related development was the Federal Circuit’s treatment of Indivior’s U.S. Patent No. 8,603,514. In separate litigation involving Dr. Reddy’s Laboratories, the Federal Circuit affirmed that the asserted claims were invalid for lack of written description because the claims covered a broad range of film compositions that was not adequately supported by the original specification. That decision weakened Indivior’s ability to rely on the ’514 patent across the generic landscape. [1]
The ruling did not automatically invalidate every Suboxone Film patent. Each patent required separate analysis of its claims, written description, enablement, obviousness, and prosecution history.
What was the Orange Book status of Suboxone Film?
Suboxone Film was protected by multiple Orange Book-listed patents covering the product and its formulation. Orange Book listings can create a 30-month approval stay when a generic applicant files a Paragraph IV certification and the brand company brings a timely infringement action.
The Orange Book position was commercially more important than the original exclusivity period because Suboxone Film had already become the primary product in Indivior’s opioid-dependence franchise. Regulatory exclusivity and patent exclusivity operated on different timelines:
| Protection |
Function |
| New-drug exclusivity |
Restricts certain FDA approvals for a defined statutory period |
| Orange Book patent listing |
Provides notice of patent claims associated with the approved product |
| Paragraph IV litigation |
Determines whether the generic can obtain approval before patent expiration |
| Patent-term adjustment |
Can extend an individual patent beyond its ordinary term |
| Pediatric exclusivity |
Can add six months to qualifying regulatory protections |
Patent expiration dates had to be calculated patent by patent, including priority claims, terminal disclaimers, patent-term adjustment, and any pediatric exclusivity. The broad Suboxone Film franchise therefore did not have a single controlling expiration date.
What generic entry risks did Actavis create?
Actavis presented three principal risks to Indivior.
Early launch after a favorable court ruling
If Actavis prevailed on validity or noninfringement, FDA approval could proceed after the statutory stay or after entry of judgment. A favorable ruling could also influence other generic defendants through collateral commercial pressure, even if it did not formally bind unrelated cases.
At-risk launch
A generic company can launch before all patent disputes are finally resolved, accepting potential damages exposure if the patent holder later prevails. At-risk launch can rapidly reduce brand volume and pricing, particularly where several generic manufacturers are ready to enter.
Price erosion after approval
Even one approved generic can reduce net pricing. Multiple generic approvals create sharper erosion because pharmacy substitution, payer controls, and wholesaler purchasing tend to accelerate share loss.
For Indivior, the risk was concentrated in Suboxone Film revenue. The litigation also affected the company’s ability to preserve market share while transitioning patients to newer products, including Sublocade, an extended-release buprenorphine injection with a separate patent and regulatory profile.
Which companies challenged Indivior’s Suboxone patents?
Indivior faced a broad generic challenge involving companies such as Actavis, Dr. Reddy’s Laboratories, Alvogen, Mylan, and other ANDA applicants. Related cases produced overlapping claim-construction and validity disputes.
The competition was legally interconnected because the same patent family was asserted against multiple defendants. A loss on a foundational patent could weaken settlement leverage in all remaining cases. Conversely, a successful infringement judgment could support later settlements, delayed-entry agreements, or licenses.
The generic competitive landscape included:
- Teva or Actavis generic buprenorphine/naloxone film;
- Dr. Reddy’s Laboratories generic film;
- Mylan generic film;
- Alvogen or associated generic applicants;
- other ANDA applicants seeking approval for the same dosage form.
Did the case involve licensing or settlement agreements?
Publicly reported Suboxone patent disputes involved settlements and commercial arrangements in the broader Indivior litigation program. Hatch-Waxman settlements commonly address:
- a defined generic launch date;
- restrictions on an at-risk launch;
- supply or authorized-generic arrangements;
- treatment of later-issued patents;
- releases and covenants not to sue;
- allocation of patent and regulatory rights.
A settlement in one defendant’s case would not necessarily resolve the Actavis action unless Actavis was a party to that agreement or the court entered a dismissal covering the relevant claims. Settlement terms can also remain confidential, limiting the ability to infer the exact launch date or economic consideration from the public docket.
What was the regulatory status of Actavis’s generic?
Actavis’s product was pursued through the ANDA pathway for buprenorphine and naloxone sublingual film. FDA approval depended on the product satisfying pharmaceutical-equivalence, bioequivalence, manufacturing, labeling, and quality requirements.
FDA approval alone did not resolve the patent dispute. The FDA generally does not adjudicate patent validity or infringement. Those issues were handled through the Paragraph IV litigation in federal court.
The regulatory and litigation tracks therefore operated separately:
- Actavis submitted an ANDA.
- Actavis certified against listed patents.
- Indivior filed the patent action.
- The statutory approval stay applied.
- The court addressed infringement and validity.
- FDA approval depended on regulatory sufficiency and the resulting patent status.
What is the commercial significance of the case?
The case was strategically important because it tested whether Indivior could preserve film exclusivity through later-generation patents after the original Suboxone protections weakened.
The commercial value of the patent estate depended on four factors:
- whether the asserted patents survived validity challenges;
- whether generic films necessarily practiced the claimed formulation features;
- whether multiple generic entrants could launch on the same date;
- whether Indivior could shift demand to products with longer-lived or differentiated protection.
Indivior’s litigation strategy relied on layering patents around the same commercial product. That approach can delay entry when claims cover unavoidable product characteristics. It becomes less effective when the patents depend on narrow manufacturing parameters, broad unsupported claim ranges, or limitations that a generic applicant can design around.
Key Takeaways
- Indivior sued Actavis Laboratories UT in the District of Delaware over a Paragraph IV ANDA for generic Suboxone Film.
- The case concerned buprenorphine/naloxone sublingual film patents, including the ’514, ’497, ’454, and ’305 patent families.
- The litigation was part of a larger Indivior campaign against generic film manufacturers.
- The ’514 patent faced a major written-description setback in related Federal Circuit litigation.
- Orange Book listings triggered Hatch-Waxman litigation and the potential 30-month FDA approval stay.
- The commercial risk was concentrated in generic substitution and pricing erosion for Suboxone Film.
- FDA approval, patent validity, infringement, and launch rights were separate legal and regulatory questions.
- Indivior’s patent strength depended more on claim-specific validity and infringement analysis than on the existence of a large patent family.
FAQs About Indivior v. Actavis Laboratories UT
What drug was at issue in Indivior v. Actavis?
The case involved a generic version of Suboxone Film, a sublingual film containing buprenorphine and naloxone for opioid-dependence treatment.
Was U.S. Patent No. 8,603,514 the only patent asserted?
No. The ’514 patent was part of a broader Suboxone Film patent program. Related litigation also involved U.S. Patent Nos. 8,900,497, 9,687,454, and 9,931,305, depending on the defendant and case posture.
Does invalidation of the ’514 patent eliminate all Suboxone Film protection?
No. Each patent has separate claims and a separate validity analysis. Invalidation of one patent does not automatically invalidate continuation patents or unrelated formulation claims.
Can Actavis launch immediately after FDA approval?
Not necessarily. FDA approval and patent clearance are separate. Actavis’s launch rights depend on the status of listed patents, court judgments, settlements, injunctions, and any applicable exclusivity period.
Why was the District of Delaware the forum?
Indivior filed in Delaware because the defendants were subject to jurisdiction there and Delaware is a principal venue for Hatch-Waxman patent litigation involving pharmaceutical companies.
References
- United States Court of Appeals for the Federal Circuit. (2020). Indivior Inc. v. Dr. Reddy’s Laboratories S.A., 18-2023, 2020 WL 886405.
- U.S. District Court for the District of Delaware. (2018). Indivior Inc. v. Actavis Laboratories UT, Inc., No. 1:18-cv-00497-RGA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent Nos. 8,603,514, 8,900,497, 9,687,454, and 9,931,305.
